Logo image of BIM.PA

BIOMERIEUX (BIM.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:BIM - FR0013280286 - Common Stock

104.6 EUR
-1.6 (-1.51%)
Last: 1/16/2026, 7:00:00 PM

BIM.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap12.38B
Revenue(TTM)4.12B
Net Income(TTM)378.00M
Shares118.36M
Float43.79M
52 Week High128.3
52 Week Low103
Yearly Dividend0.85
Dividend Yield0.79%
EPS(TTM)3.86
PE27.1
Fwd PE20.65
Earnings (Next)02-27
IPO2004-06-07
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
BIM.PA short term performance overview.The bars show the price performance of BIM.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8 -10

BIM.PA long term performance overview.The bars show the price performance of BIM.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10

The current stock price of BIM.PA is 104.6 EUR. In the past month the price decreased by -2.43%. In the past year, price decreased by -5.42%.

BIOMERIEUX / BIM Daily stock chart

BIM.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BIM.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to BIM.PA. BIM.PA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIM.PA Financial Highlights

Over the last trailing twelve months BIM.PA reported a non-GAAP Earnings per Share(EPS) of 3.86. The EPS decreased by -8.45% compared to the year before.


Industry RankSector Rank
PM (TTM) 9.17%
ROA 7.04%
ROE 9.61%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-25.82%
Sales Q2Q%7.46%
EPS 1Y (TTM)-8.45%
Revenue 1Y (TTM)8.28%

BIM.PA Forecast & Estimates

17 analysts have analysed BIM.PA and the average price target is 128.35 EUR. This implies a price increase of 22.71% is expected in the next year compared to the current price of 104.6.

For the next year, analysts expect an EPS growth of 16.45% and a revenue growth 5.19% for BIM.PA


Analysts
Analysts75.29
Price Target128.35 (22.71%)
EPS Next Y16.45%
Revenue Next Year5.19%

BIM.PA Ownership

Ownership
Inst Owners21.47%
Ins Owners0.05%
Short Float %N/A
Short RatioN/A

BIM.PA Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
2M6.DE MEDTRONIC PLC 17.39 107.89B
1MDT.MI MEDTRONIC PLC 17.01 105.52B
1SHL.MI SIEMENS HEALTHINEERS AG 19.62 52.88B
SHL.DE SIEMENS HEALTHINEERS AG 19.37 52.23B
PHI1.DE KONINKLIJKE PHILIPS NV 17.34 24.72B
PHIA.AS KONINKLIJKE PHILIPS NV 17.32 24.69B
OBCK.DE OTTOBOCK SE & CO KGAA 142.55 4.29B
DIA.MI DIASORIN SPA 22.54 4.17B
AFX.DE CARL ZEISS MEDITEC AG - BR 24.5 3.53B
DRW3.DE DRAEGERWERK AG - PREF 13.62 1.65B
DRW8.DE DRAEGERWERK AG 10.7 1.29B
ELN.MI EL.EN. SPA 22.41 1.15B

Related stock screener links

About BIM.PA

Company Profile

BIM logo image bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Company Info

BIOMERIEUX

376, chemin de l'Orme

Craponne AUVERGNE-RHONE-ALPES FR

Employees: 14451

BIM Company Website

BIM Investor Relations

Phone: 33478872000

BIOMERIEUX / BIM.PA FAQ

What does BIOMERIEUX do?

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.


What is the stock price of BIOMERIEUX today?

The current stock price of BIM.PA is 104.6 EUR. The price decreased by -1.51% in the last trading session.


Does BIM stock pay dividends?

BIOMERIEUX (BIM.PA) has a dividend yield of 0.79%. The yearly dividend amount is currently 0.85.


What is the ChartMill technical and fundamental rating of BIM stock?

BIM.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Is BIOMERIEUX (BIM.PA) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIM.PA.


Can you provide the number of employees for BIOMERIEUX?

BIOMERIEUX (BIM.PA) currently has 14451 employees.


Can you provide the ownership details for BIM stock?

You can find the ownership structure of BIOMERIEUX (BIM.PA) on the Ownership tab.